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Escalating costs of medical care have stimulated dramatic
changes in the organization and financing of health care in
the United States. Prospective payment for hospitalizations,
the growth of Health Maintenance Organizations, increased
emphasis on fee schedules and salaried arrangements to
reimburse physicians and trends toward increased use of
ambulatory services, day surgery and home care services
are some of the manifestations of change. Priorities for
health care are being reconsidered, and the prospects for
future rationing of medical services are real.
This environment creates important opportunities, as well
as challenges, for the practicing physician and for organized
medicine, including the American College of Cardiology.
On the one hand, it provides a stimulus to the medical
profession to reassess the traditional norms of medical prac-
tice'and to consider seriouslyhow cost control can be achieved
without adverse effects on the quality of care. On the other
hand, it creates incentives for constructive dialogue among
physicians, policymakers and the general public to shape
the direction of change toward an optimal balance between
individual and societal priorities.
The overriding obligation of the physician is to protect
the interests of the patient. Fundamental to fulfilling this
obligation are preservation of reasonable access to high qual-
ity health care and assurance that neither access nor quality
will be compromised by considerations of age or of the
ability to pay for health care. To put this guiding principle
into operation, we need definitions of the "best interests of
the patient," "reasonable access" and "high quality."
Moreover, arguments that "more is better" have to be sup-
ported by convincing evidence that the costs of health care
are warranted in terms of the health benefits achieved.
Considerable common ground exists among policymak-
ers, physicians and the general public. This ground has to
be carefully explored and creatively tilled.
Factors Affecting the Economics of Health
Care in the Elderly
Particular attention is being focused on the elderly in
policy debates because of their high and rapidly increasing
share of the health care market, the dramatic growth in
Medicare expenditures and special considerations related to
the cost-effectiveness of health care in the elderly.
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Effects of population growth. Persons ~65 years of
age comprise 12% of the U.S. population but consume over
one-third of expenditures for health care. Moreover, this
age group is increasing in size at a rate that is 2.5 times
that of the U.S. population as a whole. Growth is even more
rapid among the "oldest old" (persons >85 years of age).
Higher prevalences of hypertension, coronary artery dis-
ease, cancer and other chronic conditions in older persons
and increasingly frequent applications of expensive high
technologies in the elderly compound the effects of popu-
lation growth on health care costs.
Growth of Medicare expenditures. The rapid growth
of Medicare expenditures has created a virtual crisis for
federal policy makers. Medicare, enacted in 1965, has done
much to promote the health and well-being of elderly per-
sons. However, deficiencies have generated broad criticism
(1,2). Inflationary policies with regard to physician and
hospital reimbursement, unnecessary administrative com-
plexities and expenses, questions of whether the burden of
financing the program is equitably distributed and Medi-
care's failure to cover adequately the costs of long-term care
and catastrophic illnesses are some of the major targets of
criticism. Reform is underway. Prospective payment for
hospital care (Diagnosis Related Groups [DRGs]) has been
enacted; changes in mechanisms for physician reimburse-
ment are under development and it is hoped that better
financial coverage for medications, primary care and pre-
ventive services and long-term care will follow.
Cost-effectiveness of medical care for the elderly. Fi-
nally, attention has been drawn to health care for the elderly
because of the effects of age and comorbidity on the cost-
effectiveness of medical care. The costs of care for a given
episode of illness are higher in older than in younger persons
because greater comorbidity and more frequent complica-
tions lead to longer hospitalizations and increased need for
intensive care. At the same time, the health benefits of
treatments in the elderly are often less. Higher risks and
reduced potential for prolonging life, as well as coexisting
chronic disabilities, detract from expected benefits. More-
over, elderly patients may value improvements in the quality
of life more highly than added years of life. If this is so,
treatments that relieve symptoms or facilitate functional in-
dependence may be more beneficial (and cost-effective) than
"life-saving" ones. Clinical and policy decisions alike should
reflect such preferences for health outcomes.
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Cardiovascular Care of the Elderly
The treatment of cardiovascular diseases epitomizes both
the accomplishments of modern medicineand the economic
consequences of these successes. Technologic advances in
cardiology have been truly outstanding. Manx lives can be
saved today, and much suffering relieved. in ways not pos-
sible 2Q or even 10 years ago. Increases in health costs have
been equally dramatic, however, and. increasingly, ques-
tions are being raised about costs versus benefits. overutil-
ization of technologies and overpriced procedures.
Utilization and Costs of Cardiovascular Procedures
Coronary bypass surgery. Table I summarizes utili-
zation figures for cardiovascularprocedures in 1984 (3) and
estimates of their costs. More than 200,000 coronary artery
bypass operationswere performed in the United States; 360/c
of them were in persons ~65 years of age. At an average
cost of $25,000 (4), $5.1 billion was spent on coronary
artery surgery, of whichat leastSI.8 billion was for surgery
in the elderly. The question is whether the health benefits
purchased by these dollars were "worth it." or whether the
same dollars could have been spent more productively on
prevention or maternal and child care. or on improving
public education. With little doubt, coronary artery bypass
surgery can reduce the severity or relieve angina in many
patients whose pain is refractory to medical treatment. Sim-
ilarly, it has been shown to prolong life in patients with
obstruction'of the left main coronary artery or three vessel
coronary disease (5,6), especially when left ventricular
function is decreased (7). Improved survival in patients with
less extensive coronary heart disease or with normal left
ventricular function is more questionable (7). Also, recent
improvements in the treatment of angina by beta-blocking
and calcium channel blocking drugs suggest that the full
potential of newer medical treatments has not yet been ex-
plored (8).
Coronary angioplasty. The frequency with which per-
cutaneous transluminal coronary angioplasty was performed
increased dramatically from 26,000 to 46.000 procedures
between 19R3 and 1984. according to the National Center
for Health Statistics (3). In 1984, 26% of these procedures
were performed in the elderly. An important question is
whether coronary angioplasty is being used primarily in
patients who would otherwise be treated medically and.
therefore, is cost enhancing; or whether it is substituting for
coronary bypass surgery. in which case its use may be cost
saving. The answer to this question requires better infor-
mation than is available at present.
Cardiac pacemakers. The elderly have a virtual corner
on the market for cardiac pacemakers, using nearly 80% of
the 134,000 units implanted or replaced in 1994, The in-
creased usc of dual chamber pacemakers, at $6,OOO/unit
(including the pulse generator and two leads) exclusive of
physician and hospital costs. compared withaboutS4,OOO/unit
(including the pulse generator and one lead) for single cham-
ber devices adds to cost. Cost might be reduced if selection
criteria could accurately determine which patients will re-
quire only single chamber pacing at the time of implantation
and throughout the anticipated lifetime of the patient and
of the' device (9).
Cardiac catheterization and coronary angiography.
Finally, the 570,000 cardiac catheterizations and 292 ,000
coronary angiographic procedures that were performed in
1984 contribute to the total costs, both directly and through
the treatments they generate. Overall, the total cost of car-
diovascular procedures in 1984 was about $9 billion, one-
third or more of which was for procedures performed in the
Table 1. Utilization and Estimated Costs of Selected Cardiovascular Procedures in the United
States in 1984
Total
No. of Procedures Percent Unit Cos t Cu~t
Performed" > 65 Years' (Shundreds) ($nillions)
Coronary artery bypass 202 36 25t 5 .1
surgery
Percutaneous transluminal 46 26 7:j: 0 .3
coronary angioplasty
Permanent pacemaker 134 79 7§ O.Y
Cardiac catheterization 570 30 31 1.7
Coronary angiography 292 3 1 3" 0 .9
Total 8.9
*See Reference 3. ';'See Reference 4. :j:As.Hlmes: the $7.6i l figure derived in the Mayo Clinic IRd . 13),
adjusted downward (0 compensate for what appears to be an unusually long length of stay (9 .4 days') and
upward to account for inllation between 1980 and 1984 . §Assumes : one-fourth of pacemaker insertions involve
dual chamber units at $6 .000/unit and three-fourths involve single chamber units at 54.000/unit; two days of
hospitalization at $500/day ; $500 for use of the operating suite: $1 .000 for surgeon's fee . IAssume.I·: 2 days of
hospitalization at $500/da y; $500 for use of the catheterization laboratory, $500 for ancillari es and S1.000 for
physician fees ,
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elderly. Current trends toward more invasive management
of acute myocardial infarction suggest even greater use of
procedures and higher costs in future years.
Utilizatjon of cardiovascular procedures. Geographic
variations in rates of performance of cardiovascular pro-
cedures emphasize the discretionary nature of clinical de-
cisions and raise important questions about over- (or under-)
utilization. Use rates in Medicare recipients in 1981 varied
threefold among different regions of the country for coro-
nary artery bypass surgery, coronary angiography and pace-
maker insertions and varied more than fourfold for exercise
testing (Table 2) (10). These variations cannot adequately
be explained by geographic differences in disease rates or
differences in access. More likely explanations lie in varying
practice norms and factors related to the economic incentives
in health care.
Costs and benefits: non-high technology medical care.
Current emphasis on the costs of "high" technologies should
not cause us to ignore the costs and benefits of medical
treatment for hypertension or established coronary artery
disease or preventive medical services aimed at reducing
cardiovascular risk through smoking cessation or dietary
changes to lower total serum cholesterol levels. Both hy-
pertension treatment and use of beta-blocking drugs in pa-
tients after myocardial infarction are relatively cost-effec-
tive (II), and well chosen primary prevention at the
community level may even be cost saving. The costs of
treatment for hypertension and angina in the elderly are not
trivial, however, when one considers that there are as many
as 10 million persons >65 years of age with hypertension
and at least 3 million with angina in the U.S. Moreover,
uncertainties about the efficacy of treatment for isolated
systolic hypertension and treatment of very mild hyperten-
sion (90 to 94 mm Hg diastolic) raise important questions
about the effectiveness, let alone the cost-effectiveness, of
widespread pharmacologic treatment for these conditions.
1. Periodic reevaluation of patient selection criteria
for cardiac surgery, percutaneous transluminal coronary an-
gioplasty, permanent cardiac pacemakers and other diag-
nostic and treatment modalities. The best available infor-
mation should be used to examine the expected benefits and
risks in defined patient subgroups and explicit recommen-
dations should be widely promulgated.
2. Efforts to shorten hospital lengths of stay through
preoperative outpatient evaluations, optimizing treatment
before admission, earlier recognition and treatment of post-
procedure complications, better discharge planning and use
of skilled nursing facilities. The effectiveness of some of
these measures may be compromised in the elderly by lim-
itations imposed by comorbidity or by inadequate social
support systems. Nonetheless, they should be vigorously
pursued. Current third party reimbursement policies that
preclude optimal use of these cost-saving measures should
be addressed directly with relevant policymakers. Also to
be addressed are the high administrative costs of public
health care financing and monitoring systems.
3. Limiting proliferation of technologies. Cost inflation
in health care is fostered by pressures created to use (and
sometimes overuse) available technologies. In addition,
smaller programs are sometimes more costly than large ones
because they cannot realize the economies of scale. Efforts
should be made to concentrate specialized cardiovascular
care on a regional basis. Better quality of care, as well as
reduced costs, may reslIlt. Decisions on regionalization,
however, should be sensitive to the particular access and
social support needs of the elderly.
4. Emphasis on prevention. Emerging data suggest that
risk factor modification in the elderly may be of value in
preventing cardiovascular disease and its complications (see
Prevention of Cardiovascular Disease in the Elderly). This
Figure 1. Schematic representation of the trade-offs between cost
and quality of care. (Reprinted with permission from [12], 63C.)
Recommended Cost Reduction Strategies
The American College of Cardiology and other appro-
priate professional societies should explore all reasonable
avenues to cost containment. These include:
Table 2. Geographic Variations in Cardiovascular Procedure
Rates in Medicare Beneficiaries, 1981 *
Rates/lO,OOQ Beneficiaries
Procedure Mean Range
Coronary artery 13 7 to 23
bypass surgery
Coronary angiography 33 22 to 51
Exercise treadmill testing 75 43 to 182
Pacemaker implantations 50 22 to 64
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is particularly true for smoking cessation and treatment of
hypertension. Furthermore, effective prevention programs
in younger individuals may pay economic dividends through
future reductions in cardiovascular disease. Publiceducation
and community level initiatives may be cost-effective ap-
proaches to prevention and should he strongly encouraged.
5. Emphasis on Individual patient needs. High quality
care depends on close physician-patient relations, sensitivity
to individual patient preferences and mature clinical judg-
ment. Cost-containment initiatives aimed at more cost-ef-
fective use of medical technologies and inpatient services
should ensure that these vital components of clinical care
are maintained and enhanced.
Cost Containment and the Quality of Care
Possible trade-offs between the costs and quality of care
are of concern to policymakcrs, physicians and the general
public alike. The nature of these trade-offs is depicted sche-
matically in Figure I (1 2). Below and to the left of point
C, the quality of care increases dramatically as additional
resources are used. Incremental costs in relation to benefits
are low, and the cost-effectiveness is favorable. Between
points C and B, quality continues to increase with costs but
at a slower rate . Beyond point B, little, if any, improvement
in quality results, and additional resources arc essentially
wasted.
The ideal situation would be to shift the curve in the
directions shown by the dotted lines so that costs are reduced
at no loss of quality, or quality is improved with no change
or a decrease in costs. This ideal can be achieved when
increased efficiency or technologic progress results in lower
costs or when unnecessary procedures are omitted . Such
opportunities may be more frequent than is usually ac-
knowledged!
The usual case, however. is that additional medical ser-
vices contribute to the quality of care, but at a cost. The
question then becomes how much in additional cost are we
willing to incur for a given improvement in quality? Con-
troversial though this question is, it is one that is being
asked ever more frequently as the reality or limited resources
for health care becomes apparent. It is one to which we
must respond.
Cost versus quality of cardiovascular care. Resolution
of concerns about cost and quality trade-offs depend fun-
damentally on a functional definition of quality and on sys-
tematic assessment of health care activities with respect to
this standard. Any adverse effect of cost-containment ini-
tiatives can then be identified.
At present. no adequate definition of quality exists for
cardiovascular care. Such a yardstick should include mea-
sures of access and appropriateness of utilization, mortality
and morbidity (or complication) rates. and. importantly,
measures of achieved functionality, independence in living
and patient satisfaction. Moreover, a definition of quality
should reflect differences in patient preferences for alter-
native health outcomes and, in particular, should be sen-
sitive to differences in value systems between older and
younger age groups and among cultural groups.
The American College of Cardiology's conference on
cost containment concluded that " . . . cost containment and
excellent cardiologic care are compatible. if wise and useful
assessment of each cost intervention is made. Our major
responsibility is to continually assess such interventions and
their impact on care" (13). The recommendations of [his
18th Bethesda Conference should take the next step in this
initiative by making development of national quality stan-
dards for the care of patients with cardiovascular disease a
high priority. It should further encourage and assist in the
formulation of plans to assess quality and costs of care in
an ongoing manner so that cost and quality trade-oft's in the
future can be better identified than they have been in the
past.
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